Coaxil

Quick links to important sections

Coaxil

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coaxil

Quick Facts: Coaxil (Tianeptine)

Property Description
Active ingredient Tianeptine (as Tianeptine sodium)
Form Film-coated tablets (Oral preparation)
Pharmacological class Atypical Antidepressant / Selective Serotonin Reuptake Enhancer (SSRE)
General purpose Mood stabilization and emotional balance
Origin Synthetic compound

What Type of Medicine is Coaxil? (Definition and Classification)

Coaxil is a prescription-only medicine containing the single active ingredient, Tianeptine (Tianeptine sodium), and is classified as an atypical antidepressant. Tianeptine is notable for its unique classification as a Selective Serotonin Reuptake Enhancer (SSRE), which is functionally the inverse of the action exerted by most widely used SSRIs. The distinction of Tianeptine lies in its multimodal action, which is clinically recognized for influencing brain chemistry in ways that differ significantly from other psychotropic agents, suggesting a therapeutically distinct approach to managing mood disorders.

Composition, Origin, and General Purpose

Coaxil is formulated as an oral preparation in the form of film-coated tablets, using Tianeptine, a synthetic compound, as its sole active component. Tianeptine was first synthesized in the 1960s, establishing its manufactured origin. The medication's general purpose is to help stabilize emotional balance and support overall psychological resilience. Its effectiveness is supported by pharmacological studies demonstrating its ability to positively affect the brain's capacity for adaptation. The drug is typically used as pharmaceutical support in situations requiring stabilization of persistent emotional distress and low mood, offering relief by modulating key pathways related to stress and resilience. This action is generally intended to restore balance to the brain’s response to emotional overload.

What side effects are possible with Coaxil?

Possible Side Effects and Safety Information

The safety characteristics of Tianeptine (Coaxil) are defined by the official regulatory classifications, which group adverse reactions by frequency and the physiological systems affected. These classifications ensure a neutral communication of risks documented in official prescribing information.


Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented occurrence rates in clinical use:

  • Common (affecting 1 to 10 users in 100): Reactions often involve Gastrointestinal Disorders (nausea, dry mouth, abdominal pain, constipation) and Nervous System Disorders (headache, dizziness, insomnia, tremor). Cardiac effects like palpitations and tachycardia are also listed as common.
  • Uncommon (affecting 1 to 10 users in 1,000): These include hypersensitivity reactions (e.g., rash, pruritus) and certain Psychiatric Disorders such as confusion or hallucinatory behavior.
  • Rare (affecting 1 to 10 users in 10,000): Specific serious risks, including hepatitis (which may, in exceptional cases, be severe) and the potential for drug dependence or abuse, are formally documented in regulatory texts.

Population-Specific Safety Constraints

Regulatory documents establish safety limitations for certain groups:

  • Pediatrics: Tianeptine is contraindicated for use in individuals under 15 years of age.
  • Hepatic Impairment: Caution is required in patients with liver dysfunction, particularly those with severe impairment.
  • Concomitant Use: Tianeptine is contraindicated for simultaneous use with non-selective Monoamine Oxidase Inhibitors (MAOIs), requiring a mandatory washout period when switching treatments.

Time-Related Patterns

The risk of drug dependence is explicitly associated with prolonged use or the use of doses exceeding the established therapeutic range, as noted in official regulatory risk summaries.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes Tianeptine (Coaxil) overdose as a potentially life-threatening scenario requiring immediate intervention. Documented clinical manifestations primarily affect the Central Nervous System and cardiovascular system. Overdose presentations can include agitation, confusion, drowsiness, and seizures, alongside tachycardia (rapid heartbeat), hypertension (high blood pressure), and potential cardiac conduction delays.


Severe Outcomes and Emergency Action

Serious consequences documented in regulatory reports include respiratory depression (slowed or stopped breathing), coma, and death. Due to the severity of these potential outcomes, immediate medical help is mandated. If an overdose is suspected or if the affected person is experiencing trouble breathing or is hard to wake up, emergency services must be contacted immediately. All exposures require consultation with a poison help line.


Management and Considerations

Treatment for toxicity is symptomatic and supportive care, including continuous monitoring of the cardiac and respiratory status. Naloxone has been reported as an effective intervention in cases where toxicity presents as opioid-like effects. The risk of severe outcomes is increased when Tianeptine is co-exposed with other Central Nervous System depressants. Individuals with a history of opioid use disorder are identified as a population with heightened risk.

Therapeutic Uses of Coaxil

What Coaxil Treats: Main Uses and Benefits

Coaxil is generally used as an atypical antidepressant to provide focused symptomatic relief across several domains of emotional and psychological distress. The medication may be part of symptomatic management in the treatment of Major Depressive Disorder (MDD) and associated anxiety in regions where it is medically available, supporting the patient in clinical settings marked by heightened symptoms.


The medication is relevant for easing symptoms related to mood disorders and their complications. Its uses are commonly considered for MDD, generalized anxiety disorders, and conditions involving Treatment-Resistant Depression (TRD). The drug is applied in addressing symptom clusters that include persistent low mood, distressing tension, symptoms related to cognitive difficulties that interfere with daily functioning, and various physical (somatoform) complaints linked to emotional stress.

“The medication may assist with managing the complex symptom clusters present in patient groups whose primary disorder is complicated by high anxiety or somatic issues.”

This supportive role helps ease the overall symptom burden and supports general well-being during symptomatic phases.


Quick Fact: Relief for Mood and Tension
Therapeutic Domain Managing low mood in MDD and related emotional distress.
Symptom Domain Easing tension and anxiety symptoms that often co-exist with depression.
Symptomatic Benefit Assists with maintaining functional stability during periods of heightened symptoms and functional strain.
Use Context Applied in cases where patients experience complex, co-existing emotional and physical symptoms.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Coaxil — Official Regulatory Information

This section describes the population eligibility rules for Coaxil (Tianeptine) strictly based on official governmental regulatory documents.


Eligibility Scope

Category Status According to Regulatory Documents
Populations for whom use is allowed (as stated in label) Adults (18 years and older) in countries where the product is approved.
Populations for whom use is not recommended (if applicable) Adolescents (aged 15 to 18 years); Pregnant individuals; Breastfeeding individuals.
Populations for whom use is contraindicated Children under 15 years old; Patients with known hypersensitivity to tianeptine or any excipient.

Age- and Condition-Based Eligibility

Category Regulatory Statement
Age-related eligibility rules Contraindicated for children and adolescents under 15 years; use in subjects over 70 years requires restricted dosage.
Condition-specific eligibility rules Use with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated; dose adjustments are necessary for patients with renal insufficiency.
Pregnancy and lactation eligibility status Pregnancy: Not recommended; use only if vital. Lactation: Not recommended due to insufficient safety data.

Connection to the overall eligibility profile

Regulatory documents define eligibility primarily by establishing adult use as the standard allowed population while strictly enforcing absolute contraindications for pediatric age groups and co-administration with MAOIs. Beyond these exclusions, eligibility is structured by specific limitations, creating conditional use for older adults and patients with impaired renal function, directly reflecting regulatory requirements for safe use.

What should I know about interactions with other medicines?

Contraindicated Combinations and Timing Rules

Tianeptine's interaction profile is primarily defined by specific regulatory restrictions governing co-administration with other products and certain physiological conditions.

The combination of Coaxil with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated (prohibited) due to the risk of serious adverse effects. A mandatory two-week (14-day) wash-out period must be observed when switching from an MAOI to Tianeptine. When switching from Tianeptine to an MAOI, a minimum 24-hour separation is required.

Pharmacodynamic and Exposure Risks

Co-administration with CNS depressants or sedative medications may result in an additive pharmacodynamic effect, potentially leading to enhanced central nervous system depression. The official label notes that alcohol should be avoided as it can cause enhanced adverse effects and may also increase Tianeptine plasma levels by decreasing the rate of drug breakdown. Long-term use of Aspirin is also documented to potentially increase Tianeptine concentrations. Tianeptine has a low risk of CYP450-mediated drug-drug interactions, as its metabolism is predominantly extrarenal.

Population-Specific Constraints

Regulatory documentation notes that interactions related to drug clearance are relevant in specific populations. For elderly patients (over 70 years) and individuals with renal insufficiency, the potential for altered drug elimination requires a restriction on the maximum daily amount administered due to an elevated risk of increased Tianeptine exposure.

Mechanism of Action

Coaxil (tianeptine) is an atypical agent that works through multiple distinct mechanisms at the biological level, primarily modulating two distinct systems to achieve its effects.

Glutamatergic Neurotransmission Modulation

This domain involves Coaxil's key action on the glutamatergic system, essential for synaptic plasticity and nervous system signaling. The compound stabilizes glutamatergic pathways by modulating the activity of AMPA and NMDA receptors. This mechanism modulates neural excitability following heightened signaling input, leading to predictable stabilization of neural excitability and influencing cellular plasticity and functional response.


Opioid Receptor Full Agonism

Coaxil also acts as a full agonist at the mu-opioid receptor (MOR). Engaging the MOR initiates a signaling cascade, which includes the potential for downstream effects like the upregulation of the mTOR pathway. This mechanism contributes to the overall effect profile via pathway-level adjustments and results in rapid pathway adjustment.


Serotonin Reuptake Enhancement

Coaxil was historically characterized as a selective serotonin reuptake enhancer (SSRE), an action that affects the serotonin transporter (SERT) by increasing the re-entry of serotonin into the presynaptic neuron. This pathway effect results in altered serotonin concentration within the synaptic cleft.

Dosage and Administration Information

Administration and Dosage Protocol

Coaxil (tianeptine sodium) is designed for oral administration using a 12.5 mg film-coated tablet. The prescribed dosing schedule is detailed within regulatory documentation and centers on a frequent daily pattern tied directly to food consumption.

The standard labeled regimen for adults consists of taking one 12.5 mg tablet three times per day, establishing a total daily dose of 37.5 mg. A key procedural requirement is that each dose must be consumed at the beginning of the main meals—morning, midday, and evening—a mandatory instruction for proper administration.


Population-Specific Adjustments

Official protocols clearly define dose adjustments necessary for certain patient populations. For older adults over 70 years of age or individuals diagnosed with renal impairment, the total daily intake must be restricted to a maximum of two tablets (25 mg total). This adjustment is a required condition of use. Importantly, for chronic alcoholics, whether they are cirrhotic or not, the standard 37.5 mg daily regimen remains unchanged.


Discontinuation Guidance

The official procedural guidance for concluding therapy emphasizes that the dosage should always be reduced gradually over a defined period when stopping treatment. This tapering is a required administrative step and prevents abrupt cessation of the usage pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coaxil

This overview summarizes the available research and clinical studies for Coaxil (Tianeptine) as reported in scientific literature and by regulatory bodies, focusing only on the type of evidence that exists and the research scope. This information is purely descriptive and should not be used for making personal health decisions.


Evidence for Use in Major Depressive Disorder (MDD)

Research exploring Coaxil's role in Major Depressive Disorder primarily involves short-term randomized controlled trials (RCTs), lasting typically 8 weeks to 3 months, to explore the patterns of change associated with Coaxil administration. These studies were used in research exploring how symptoms change over time, comparing the results observed with Coaxil against either an inactive substance (placebo) or against other established antidepressant medications. These trials typically monitored adults with moderate to severe recurrent MDD.

The findings describe patterns observed in the studies, reporting measurements of symptom severity change from the start of the study to the end. For short-term evaluation of MDD symptoms, research describes patterns measured during studies that included comparisons to other standard antidepressant treatments.

However, the existing studies provide limited insight into long-term outcomes. The focus on short-term results means that the durability of symptomatic changes and how patients fare over extended periods (longer than six months) is less characterized by high-quality, controlled data. The research does not determine whether an individual will respond similarly over the long run.

Evidence for Managing Co-existing Anxiety Symptoms

The research related to anxiety and tension is often derived from secondary endpoint analyses of the main MDD trials, meaning the primary focus was depression, but researchers also monitored other outcomes related to physical discomfort and emotional strain. Some trials described patterns related to changes measured in these co-occurring anxiety and somatic symptoms. Research focusing on standalone anxiety disorders remains limited, as most available findings reflect studies where the primary focus was Major Depressive Disorder.

What is Still Uncertain About the Research

The research provides context but not individual predictions, highlighting several key areas where evidence remains limited. Long-term effects are not fully established, particularly concerning maintenance of wellness and prevention of future symptom episodes, due to the limited duration of controlled trials. Research focusing on the highly selected patient groups in Treatment-Resistant Depression has been exploratory, meaning the sample sizes were modest, and comparative evidence is lacking against standard treatment approaches. Furthermore, findings were mixed across studies when examining whether an earlier change in symptoms was observed compared to standard treatments.

Frequently Asked Questions (FAQ)

Common questions about Coaxil (FAQ)

Q: Is Coaxil considered a tricyclic antidepressant (TCA) or something else?

While tianeptine is chemically classified as a tricyclic antidepressant (TCA) due to its core structure, official information describes it as an atypical antidepressant.

This is because its functional mechanism in the body is described as operating differently from typical TCA medicines.


Q: Can Coaxil cause drowsiness or affect my ability to drive?

Official product information notes that common side effects can include dizziness and drowsiness.

Because of these potential effects, official warnings advise using caution regarding driving or operating machinery until the patient knows how the medicine affects them.


Q: Are there any known long-term side effects associated with Coaxil use?

According to official regulatory documents, the primary long-term risk noted is the potential for drug dependence or abuse.

This risk is especially emphasized with prolonged use or when taking doses higher than the established therapeutic range.


Q: What happens if I stop taking Coaxil suddenly?

Regulatory guidance strongly advises against the abrupt discontinuation of this medicine.

Stopping suddenly can lead to withdrawal symptoms, which have been noted to resemble those seen with opioids, and may include physical discomfort like agitation, anxiety, and muscle pain.


Q: Is there a risk of dependence or withdrawal symptoms with Coaxil?

Official documents explicitly warn that there is a risk of drug dependence, abuse, and withdrawal symptoms associated with Coaxil.

This risk is heightened when higher than prescribed doses are used or if the treatment is stopped suddenly without gradual reduction.


Q: Do I need to avoid any specific foods or drinks while taking Coaxil?

Regulatory warnings clearly state that alcohol should be avoided due to the potential for enhanced adverse effects.

However, clinical studies generally indicate that the consumption of food has only a modest effect on the drug's absorption.


Q: Is Coaxil used to treat anxiety in addition to depression?

The primary indication for Coaxil is Major Depressive Disorder (MDD).

However, clinical data often recognize the drug's anxiolytic properties, meaning it can have effects on co-occurring symptoms of anxiety and tension, which are sometimes monitored as secondary outcomes in research.


Q: Do studies suggest Coaxil is non-inferior to other common treatments?

Clinical research often involves studies comparing Coaxil to other established antidepressant medicines.

Evidence from these comparative studies has sometimes suggested that the effects observed are similar or 'non-inferior' to the effects measured with standard treatments for certain symptoms.


Q: What is the evidence regarding Coaxil's effect on stress or chronic pain?

Official documents note that research has explored the drug's effect on somatic symptoms (physical discomfort) and emotional strain.

Some studies have also investigated its role in managing stress-related cognitive impairment and certain conditions associated with chronic pain, such as Irritable Bowel Syndrome.


Q: Can Coaxil affect kidney function?

Regulatory information states that patients with pre-existing kidney (renal) impairment require a dosage adjustment because of how the body clears the medicine's byproducts.

Official documents focus on the need for dosage adjustment for patients with pre-existing kidney (renal) impairment.


Q: Why is Coaxil not approved in some countries, like the U.S.?

According to warnings from health authorities, Coaxil (tianeptine) is not approved for medical use in countries like the United States due to specific safety concerns.

These concerns center around the significant potential for abuse, addiction, and the risk of severe adverse health effects, particularly when high doses are consumed.


Q: Can Coaxil cause issues with blood pressure?

Official adverse event reports indicate that cardiovascular effects, such as a fast heart rate (tachycardia) and elevated blood pressure, have been reported.

These effects have been noted in cases of both prescribed use and misuse of the medicine.


Q: Why is a prescription required for Coaxil?

Coaxil is designated as a prescription-only medicine in approved regions due to its classification and pharmacological profile.

This requirement is primarily in place because of the potential for abuse and dependence, which is linked to the medicine's activity on certain opioid receptors in the body.


Q: Do official documents mention any specific warnings for people with suicidal thoughts?

Official warnings from health authorities specify a risk of suicidal ideation (thoughts) or behavior associated with the use of tianeptine.

This warning is particularly emphasized for younger patient groups, including children, adolescents, and young adults.


Q: What is the half-life of Coaxil?

Clinical pharmacokinetic studies show that the medicine is quickly processed by the body.

The mean elimination half-life—the time it takes for half the drug to be eliminated—is relatively short, generally noted to be about 2.5 hours in healthy adults.


Q: What are the signs of taking too much Coaxil?

Regulatory reports on overdose situations detail a range of serious symptoms.

These may include altered mental status, confusion, agitation, a fast heart rate (tachycardia), high blood pressure, seizures, and potentially slowed or shallow breathing.


Q: Does taking Coaxil affect my concentration or memory?

Adverse event reports have sometimes included confusion as a side effect.

Conversely, some research has suggested that the medicine's unique action may help protect cognitive functions, such as learning and memory, from being impaired by stress.

How should Coaxil be stored and disposed of?

How to Store and Dispose of Coaxil (Tianeptine)

Official regulatory documents define strict conditions for the storage and disposal of Coaxil tablets to maintain product integrity.

Storage Requirements

Coaxil must be stored at a temperature not exceeding 30 C (86 F). The medicine requires protection from moisture and should be kept in the original blister packaging until use.

It is mandatory that Coaxil be stored securely out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Any unused or expired Coaxil product must be disposed of strictly in accordance with local requirements for pharmaceutical waste. The tablets should not be discarded into household trash or wastewater to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coaxil found in:

A-Z Index: